HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells

被引:39
作者
Ammerpohl, O
Thormeyer, D
Khan, Z
Appelskog, IB
Gojkovic, Z
Almqvist, PM
Ekström, TJ
机构
[1] Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Stockholm, Sweden
[2] Karolinska Inst, Ctr Genom & Bioinformat, Stockholm, Sweden
[3] ZGene AS, DK-2800 Lyngby, Denmark
[4] AstraZeneca R&D, Sodertalje, Clin Sci, S-15185 Sodertalje, Sweden
关键词
HSV-tk; bystander killing; HDAC inhibitor; 4-phenylbutyrate; ganciclovir; glioma; gap junction;
D O I
10.1016/j.bbrc.2004.09.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant glioma patients have a dismal prognosis with an urgent need of new treatment modalities. Previously developed gene therapies for brain tumors showed promising results in experimental animal models, but failed in clinical trials due to low transfection rates and insufficient expression of the transgene in tumor cells, as well as low bystander killing effects. We have previously shown that the histone deacetylase inhibitor 4-phenylbutyrate (4-PB) enhances gap junction communication between glioma cells in culture. In this study, we demonstrate an activation of recombinant HSV-tk gene expression, and a dramatic enhancement of gap junction-mediated bystander killing effect by administration of the HSV-tk prodrug ganciclovir together with 4-PB. These findings that 4-PB potentiates "suicide gene" expression as well as enhances gap junctional communication and bystander killing of tumor cells justify further testing of this paradigm as an adjunct to suicide gene therapy of malignant gliomas. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 14
页数:7
相关论文
共 40 条
  • [21] A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma
    Klatzmann, D
    Valery, CA
    Bensimon, G
    Marro, B
    Boyer, O
    Mokhtari, K
    Diquet, B
    Salzmann, JL
    Philippon, J
    [J]. HUMAN GENE THERAPY, 1998, 9 (17) : 2595 - 2604
  • [22] The epigenome as a target for cancer chemoprevention
    Kopelovich, L
    Crowell, JA
    Fay, JR
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (23): : 1747 - 1757
  • [23] Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms
    Kruse, CA
    Lamb, C
    Hogan, S
    Smiley, WR
    Kleinschmidt-DeMasters, BK
    Burrows, FJ
    [J]. CANCER GENE THERAPY, 2000, 7 (01) : 118 - 127
  • [24] NATIONAL SURVEY OF PATTERNS OF CARE FOR BRAIN-TUMOR PATIENTS
    MAHALEY, MS
    METTLIN, C
    NATARAJAN, N
    LAWS, ER
    PEACE, BB
    [J]. JOURNAL OF NEUROSURGERY, 1989, 71 (06) : 826 - 836
  • [25] Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
    Marks, PA
    Richon, VM
    Rifkind, RA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15): : 1210 - 1216
  • [26] Mesnil M, 2000, CANCER RES, V60, P3989
  • [27] Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model
    Moriuchi, S
    Wolfe, D
    Tamura, M
    Yoshimine, T
    Miura, F
    Cohen, JB
    Glorioso, JC
    [J]. GENE THERAPY, 2002, 9 (09) : 584 - 591
  • [28] Okada H, 1996, GENE THER, V3, P957
  • [29] Oligny Luc Laurier, 2003, Adv Pediatr, V50, P59
  • [30] Robe PA, 2004, INT J ONCOL, V25, P187